Torrent Pharma Q3 net profit surges 26% on strong revenue growth, declares ₹29 dividend – CNBC TV18

Pharmaceutical company Torrent Pharmaceuticals Ltd on Friday (February 13) reported a net profit of ₹635 crore in Q3 FY26, up 26.3% from ₹503 crore in the same period last year.

The company’s revenue grew 17.6% to ₹3,303 crore versus ₹2,809 crore in Q3 FY25. EBITDA increased 19% to ₹1,088 crore from ₹914 crore in the year-ago period. The EBITDA margin stood at 32.9%, slightly up from 32.5% in Q3 FY25.

India

Revenue in India for Q3 FY26 was ₹1,798 crore, up 14% year-on-year. According to AIOCD PharmaTrac secondary market data, the Indian Pharmaceutical Market (IPM) grew 10% during the quarter. Torrent Pharma outperformed the market in chronic and sub-chronic therapies, led by the cardiac, gastro, and diabetes (OAD) segments. For 9M FY26, India revenues stood at ₹5,430 crore, up 12% from the same period last year.

Also Read: Torrent Pharma FDA inspection ends with clean chit; co hikes JB Chemicals stake to 48.75%

Brazil

Torrent’s Brazil revenues reached ₹371 crore, up 27% year-on-year. On a constant currency basis, revenues were R$224 million, up 10%. As per IQVIA data, Torrent grew 13% versus market growth of 7%, driven by top brands and recent launches. The company currently has 60 products under ANVISA review. For 9M FY26, Brazil revenues were ₹907 crore, up 21% (constant currency: R$564 million, up 13%).

United States

The US business posted revenues of ₹321 crore, up 19% from the prior year. Constant currency revenues were $36 million, up 12%. Recent product launches in the US achieved their target market shares. For 9M FY26, US revenues were ₹967 crore (constant currency: $111 million, up 16%).

Germany

Germany revenues grew 8% to ₹304 crore, while constant currency revenues were EUR 29 million, down 6%. Growth was affected by supply disruptions at a third-party supplier. For 9M FY26, Germany revenues were ₹916 crore (constant currency: EUR 91 million, down 3%).

Also Read: Torrent Pharma Q1 Result | Net profit rises 20% to ₹548 crore; revenue, margin improves

Torrent Pharma announced an interim dividend of ₹29 per equity share of ₹5, fully paid up, representing 580% of the face value. The dividend is expected to be paid or dispatched on or around 6th March 2026.

Shares of Torrent Pharmaceuticals Ltd ended at ₹4,074.05, down by ₹7.55, or 0.18%, on the BSE.